BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2024
- Revenue for nine months ended Feb 29, 2024, was $46,792,353, an increase from the previous year
- Net income reached $1,659,170 for the same period, showing improvement from last year
- Income before income tax grew to $2,288,970 compared to the previous year
- Visit www.bioqual.com for detailed unaudited third quarter results of fiscal year 2024
- None.
Nine Months Ended |
Three Months Ended |
|||||||||||
February 29 & 28, |
February 29 & 28, |
|||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||
Revenue |
$ |
46,792,353 |
$ |
46,595,270 |
$ |
15,344,027 |
$ |
14,107,568 |
|
|||
Income Before Income Tax |
$ |
2,288,970 |
$ |
2,174,295 |
$ |
379,226 |
$ |
(1,610,199 |
) |
|||
Net Income |
$ |
1,659,170 |
$ |
1,537,695 |
$ |
275,026 |
$ |
(1,139,699 |
) |
|||
Basic Earnings per Share of Common Stock |
$ |
1.86 |
$ |
1.72 |
$ |
0.31 |
$ |
(1.27 |
) |
|||
Diluted Earnings per Share of Common Stock |
$ |
1.86 |
$ |
1.72 |
$ |
0.31 |
$ |
(1.27 |
) |
|||
Weighted Average |
||||||||||||
Number of Shares Outstanding For Basic Earnings Per Share |
|
894,416 |
|
894,416 |
|
894,416 |
|
894,416 |
||||
Weighted Average |
||||||||||||
Number of Shares Outstanding For Diluted Earnings Per Share |
|
894,401 |
|
894,416 |
|
894,407 |
|
894,408 |
||||
For more detail related to the fiscal year 2024 unaudited third quarter results, please visit our web site at www.bioqual.com.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422839563/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
FAQ
What was BIOQUAL's (BIOQ) revenue for the nine months ended February 29, 2024?
How did BIOQUAL's (BIOQ) net income compare to the previous year for the same period?
What was the income before income tax for BIOQUAL (BIOQ) for the third quarter of fiscal year 2024?
Where can more detailed information on BIOQUAL's (BIOQ) unaudited third quarter results for fiscal year 2024 be found?
